Panion & BF Biotech Inc. (1760) AI Stock Analysis

Panion & BF Biotech Inc.

(TWSE:1760)

Select Model

Rating:66Neutral

Price Target:TWD 53.00▲(11.11% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is supported primarily by improved profitability and a strong balance sheet. Positive valuation and dividend characteristics provide additional support, while weak technical momentum and inconsistent cash conversion are the main risks.

Positive Factors

Improving ProfitabilityRising operating and net margins indicate stronger earnings leverage and improved profitability across the business. Consistently strong gross margins provide a durable base for funding development, commercialization, and future growth while reducing the impact of moderate revenue fluctuations.

Negative Factors

Choppy Revenue GrowthThe uneven revenue trajectory makes the company’s growth profile less predictable and complicates planning for a biopharmaceutical portfolio. A sharp prior decline followed by only modest recent growth could limit operating leverage and make sustained earnings expansion dependent on individual product performance.

Panion & BF Biotech Inc. (1760) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 4.13B
Dividend Yield: 4.19%
Average Volume (3M): 117.43K
Price to Earnings (P/E): 24.7
Beta (1Y): 0.28
Revenue Growth: 1.43%
EPS Growth: -5.24%
Country: TW
Employees: 321
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Panion & BF Biotech Inc. Business Overview & Revenue Model

Company Description

Panion & Bf Biotech Inc. is a biopharmaceutical firm operating in Taiwan, engaged in the production and distribution of a diverse range of pharmaceutical goods. Its offerings cater to several key therapeutic and wellness segments, including medical a...

Panion & BF Biotech Inc. Financial Statement Overview

Summary

Profitability improved materially and the balance sheet is solid, with manageable leverage. Positive but declining operating and free cash flow, along with uneven revenue growth, limit the score.

Income Statement

78Positive

Balance Sheet

84Very Positive

Cash Flow

63Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.11B	2.06B	2.03B	1.88B	2.40B	1.90B
Gross Profit	1.11B	1.12B	1.07B	974.40M	1.32B	912.14M
EBITDA	466.16M	446.27M	405.32M	327.22M	504.62M	343.05M
Net Income	214.82M	190.17M	124.52M	77.22M	182.34M	104.40M
Balance Sheet
Total Assets	3.22B	3.23B	3.21B	3.24B	3.09B	2.95B
Cash, Cash Equivalents and Short-Term Investments	471.42M	460.32M	558.37M	534.63M	464.26M	348.89M
Total Debt	603.26M	647.70M	704.86M	727.83M	482.33M	502.56M
Total Liabilities	1.35B	1.27B	1.29B	1.32B	1.09B	1.02B
Stockholders Equity	1.87B	1.95B	1.92B	1.91B	2.01B	1.93B
Cash Flow
Free Cash Flow	188.95M	150.37M	165.49M	-3.81M	291.23M	231.22M
Operating Cash Flow	333.17M	298.71M	351.19M	177.42M	489.87M	401.23M
Investing Cash Flow	-154.40M	-133.37M	-158.77M	-155.27M	-144.47M	-215.05M
Financing Cash Flow	-232.44M	-262.85M	-170.51M	48.67M	-167.39M	-217.76M

Panion & BF Biotech Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:1760 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:1760	66Neutral	TWD 4.23B	24.71	―	4.19%	1.43%	-5.24%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:3176	42Neutral	TWD 4.62B	-16.65	―	―	1.11%	-94.39%
TW:4726	35Underperform	TWD 4.76B	-12.16	―	―	52.81%	38.53%

* General Sector Average

Performance Comparison

TW:1760 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:1760	Panion & BF Biotech Inc.	47.70	-17.70	-27.07%
TW:1271	SunWay Biotech Co., Ltd.	58.80	-2.38	-3.88%
TW:3176	Medigen Biotechnology Corporation	30.10	0.15	0.50%
TW:4726	Mycenax Biotech Inc.	22.40	-10.85	-32.63%
TW:6610	TWi Biotechnology, Inc	17.50	-18.80	-51.79%
TW:6634	Sinew Pharma, Inc.	63.20	22.70	56.05%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Panion & BF Biotech Inc. AI Stock Analysis